Ad
related to: implanted ports for cancer cells impact factor
Search results
Results From The WOW.Com Content Network
An implanted port is less obvious than a tunneled catheter and requires little daily care. It has less impact on a person's activities than a PICC line or a tunneled catheter. Surgically implanted infusion ports are placed below the clavicle (infraclavicular fossa), with the catheter threaded into the heart (right atrium) through a large vein.
Chest X-ray showing an implanted port. A port is more correctly known as a "totally implantable venous access device". They are also commonly referred to as a Portacath or Chemo port. Brand names include Eco Port, Clip-a-Port, SmartPort, Microport, Bardport, PowerPort, Passport, Port-a-Cath, Infuse-a-Port, Medi-Port, and Bioflo.
An implanted central venous catheter, also called a port a "cath" or "port-a-cath", is similar to a tunneled catheter, but is left entirely under the skin and is accessible via a port. Medicines are injected through the skin into the catheter. Some implanted ports contain a small reservoir that can be refilled in the same way.
It consists of a catheter in one lateral ventricle attached to a reservoir implanted under the scalp. It is used to treat brain tumors, leukemia/lymphoma or leptomeningeal disease by intrathecal drug administration. In the palliative care of terminal cancer, an Ommaya reservoir can be inserted for intracerebroventricular injection (ICV) of ...
The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years. [14] [15]
Cancer Discovery is a monthly peer-reviewed medical journal published by the American Association for Cancer Research. It covers research and clinical trials related to the study of cancer. The editors-in-chief are Lewis C. Cantley and Luis A. Diaz. [1] The journal was established in 2011. [1]
Cancer Cell is internationally regarded as one of the top cancer research and oncology journals. According to the Journal Citation Reports, the 2022 impact factor of the journal is 50.3. It is part of the Cell Press portfolio, which is owned by Elsevier. Issues are published monthly in print and online versions.
Cancer Cytopathology is a monthly peer-reviewed scientific journal which covers practice of cytopathology and its related oncology-based disciplines. It is one of three official journals of the American Cancer Society and is published by Wiley-Blackwell on behalf of the society. The current editor-in-chief is William C. Faquin.